Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Current Deferred Revenue (2019 - 2025)

Apyx Medical's Current Deferred Revenue history spans 7 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 15.0% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, down 15.0%, while the annual FY2025 figure was $1.7 million, 15.0% down from the prior year.
  • Current Deferred Revenue reached $1.7 million in Q4 2025 per APYX's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.3 million in Q4 2022 to a low of $1.7 million in Q4 2023.
  • Average Current Deferred Revenue over 5 years is $1.9 million, with a median of $1.9 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 216.67% in 2021, then fell 26.09% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.9 million in 2021, then rose by 21.05% to $2.3 million in 2022, then fell by 26.09% to $1.7 million in 2023, then grew by 17.65% to $2.0 million in 2024, then decreased by 15.0% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Current Deferred Revenue are $1.7 million (Q4 2025), $2.0 million (Q4 2024), and $1.7 million (Q4 2023).